Quality Strategy and Tactics

Bringing clarity to quality 

The payer paradigm is shifting to one that is focused on defining value as the balance of cost and quality. Turn to Xcenda in this evolving environment for evidence that demonstrates the clinical impact of products, the link to quality measures, and how these will drive the future of product lifecycle planning.  Let us help you navigate through the growing policies and measures that affect your products to demonstrate quality outcomes that matter most.  

Develop a quality strategy that meets your needs. Strategic and tactical offerings include: 

  • Quality planning roadmaps and workshops
  • Therapeutic area quality task forces 
  • Landscape assessment and monitoring of measures and metrics 
  • Quality and pharmacoeconomic evidence generation 
  • Triple Aim-focused value proposition development  
  • Quality market research
  • Metric and program public comment opportunities
  • Field training and education
  • Payment reform and quality workshops

Meet the experts

Michelle Friedman, MPH

Michelle is associate director of Global Health Economics and Outcomes Research at Xcenda. In this role, she leads health economics and strategic consulting engagements that help manufacturers demonstrate, realize, and communicate product value to key stakeholders. Her work includes the development of value propositions and evidence-generation planning for individual products and therapeutic portfolios. She also has expertise in leading and managing advisory boards, literature reviews, pharmacoeconomic models, retrospective database studies, and dossiers along with extensive background in academic research. 

Start a conversation

We’re value drivers and problem solvers. Let us connect you with experts who understand your world and what success demands.
Contact us